



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_166_25

You asked:

I am analysing the treatment of dermatological conditions in the UK so how many patients were treated in the last 4 months (December 2024 to March 2025) by the dermatology department with each of the following products:

- Abrocitinib
- Baricitinib
- Dupilumab
- Lebrikizumab
- Tralokinumab
- Upadacitinib
- Nemolizumab

Our response:

Please find below as requested, a table populated with the information Medicines Management are able to provide at this current time. The period the data relates to is 1st December 24 to the 31st March 2025 the latest 4 months available.

Medicine	Number of Patients
Abrocitinib	6
Baricitinib	7
Dupilumab	217
Lebrikizumab	9
Tralokinumab	10
Upadacitinib	13
Nemolizumab	0